1. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews
   Marina T Van Leeuwen et al, 2020, JNCI Cancer Spectrum CrossRef
2. Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trials
   Yong Xin et al, 2016, Cancer Medicine CrossRef
3. Tumor dosimetry for I-131 trastuzumab therapy in a Her2+ NCI N87 xenograft mouse model using the Siemens SYMBIA E gamma camera with a pinhole collimator
   Young Sub Lee et al, 2015, Journal of Instrumentation CrossRef
4. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort
   Benjamin Daniels et al, 2017, BMJ Open CrossRef
5. Chimiothérapie néo-adjuvante des cancers du sein HER2-positifs et triple-négatifs
   Anthony Gonçalves, 2016, Bulletin du Cancer CrossRef
6. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer
   Yan Chen et al, 2018, Medicine CrossRef
7. The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?
   Anthony Gonçalves et al, 2017, Expert Review of Anticancer Therapy CrossRef